Technical Analysis for PALI - Palisade Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -7.10% | |
| Fell Below 50 DMA | Bearish | -7.10% | |
| Wide Bands | Range Expansion | -7.10% | |
| Gapped Down | Weakness | -7.10% | |
| MACD Bullish Signal Line Cross | Bullish | -28.64% | |
| Pocket Pivot | Bullish Swing Setup | -28.64% | |
| Calm After Storm | Range Contraction | -28.64% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 19 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 2 % | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Palisade Bio, Inc. Description
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Surgery Abdominal Pain Digestive System Gastrointestinal Tract
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 36.6 |
| 52 Week Low | 3.82 |
| Average Volume | 656,409 |
| 200-Day Moving Average | 10.79 |
| 50-Day Moving Average | 5.81 |
| 20-Day Moving Average | 5.39 |
| 10-Day Moving Average | 5.05 |
| Average True Range | 1.05 |
| RSI (14) | 44.44 |
| ADX | 24.97 |
| +DI | 40.66 |
| -DI | 19.38 |
| Chandelier Exit (Long, 3 ATRs) | 6.49 |
| Chandelier Exit (Short, 3 ATRs) | 6.98 |
| Upper Bollinger Bands | 6.81 |
| Lower Bollinger Band | 3.97 |
| Percent B (%b) | 0.26 |
| BandWidth | 52.61 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.27 |
| MACD Histogram | 0.0296 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.57 | ||||
| Resistance 3 (R3) | 5.59 | 5.33 | 5.42 | ||
| Resistance 2 (R2) | 5.33 | 5.11 | 5.32 | 5.37 | |
| Resistance 1 (R1) | 5.02 | 4.98 | 5.18 | 5.00 | 5.33 |
| Pivot Point | 4.76 | 4.76 | 4.84 | 4.75 | 4.76 |
| Support 1 (S1) | 4.45 | 4.54 | 4.61 | 4.43 | 4.09 |
| Support 2 (S2) | 4.19 | 4.41 | 4.18 | 4.05 | |
| Support 3 (S3) | 3.88 | 4.19 | 4.00 | ||
| Support 4 (S4) | 3.86 |
